1. Home
  2. HR vs PTCT Comparison

HR vs PTCT Comparison

Compare HR & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Healthcare Realty Trust Incorporated

HR

Healthcare Realty Trust Incorporated

HOLD

Current Price

$20.11

Market Cap

6.5B

Sector

Real Estate

ML Signal

HOLD

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$73.87

Market Cap

5.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HR
PTCT
Founded
1992
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
5.7B
IPO Year
2006
2006

Fundamental Metrics

Financial Performance
Metric
HR
PTCT
Price
$20.11
$73.87
Analyst Decision
Hold
Buy
Analyst Count
8
17
Target Price
$19.29
$80.65
AVG Volume (30 Days)
4.1M
984.0K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
5.20%
N/A
EPS Growth
60.77
264.48
EPS
N/A
N/A
Revenue
$1,180,546,000.00
$264,734,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.14
$17.70
P/E Ratio
N/A
$8.29
Revenue Growth
N/A
36.19
52 Week Low
$14.09
$43.18
52 Week High
$20.46
$87.50

Technical Indicators

Market Signals
Indicator
HR
PTCT
Relative Strength Index (RSI) 72.42 60.74
Support Level $17.44 $72.21
Resistance Level N/A $73.79
Average True Range (ATR) 0.40 3.40
MACD 0.17 0.03
Stochastic Oscillator 87.24 60.61

Price Performance

Historical Comparison
HR
PTCT

About HR Healthcare Realty Trust Incorporated

Healthcare Realty Trust Inc is a healthcare facility real estate investment trust. The company focuses on owning, leasing, and managing outpatient facilities and other healthcare properties. The company works to invest in outpatient facilities that are integral to a hospital's operations. It generates all of its revenue in the United States.

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Share on Social Networks: